MX336323B - Anticuerpos de anti-poliubiquitina y metodos de uso. - Google Patents

Anticuerpos de anti-poliubiquitina y metodos de uso.

Info

Publication number
MX336323B
MX336323B MX2012011829A MX2012011829A MX336323B MX 336323 B MX336323 B MX 336323B MX 2012011829 A MX2012011829 A MX 2012011829A MX 2012011829 A MX2012011829 A MX 2012011829A MX 336323 B MX336323 B MX 336323B
Authority
MX
Mexico
Prior art keywords
methods
polyubiquitin antibodies
polyubiquitin
antibodies
same
Prior art date
Application number
MX2012011829A
Other languages
English (en)
Other versions
MX2012011829A (es
Inventor
Robert F Kelley
Vishva Dixit
Marissa L Matsumoto
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of MX2012011829A publication Critical patent/MX2012011829A/es
Publication of MX336323B publication Critical patent/MX336323B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4703—Regulators; Modulating activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2440/00—Post-translational modifications [PTMs] in chemical analysis of biological material
    • G01N2440/36—Post-translational modifications [PTMs] in chemical analysis of biological material addition of addition of other proteins or peptides, e.g. SUMOylation, ubiquitination

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Neurology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Neurosurgery (AREA)

Abstract

La presente invención se refiere a un anticuerpo monoclonal aislado que se une a poliubiquitina ligada a K11, en donde el anticuerpo comprende una secuencia HVR-L1 seleccionada de SEQ ID Nos.: 2 y 57-60, una secuencia HVR-L2 seleccionada de SEQ ID Nos.: 3 y 61, una secuencia HVR-L3 de SEQ ID NO: 4, una secuencia HVR-H1 seleccionada de SEQ ID Nos.: 6 a 11, una secuencia HVR-H2 seleccionada de SEQ ID Nos.: 12 a 17 y 67 y una secuencia HVR-H3 seleccionada de SEQ ID Nos: 18 a 23, 68 y 69.
MX2012011829A 2010-04-15 2011-04-14 Anticuerpos de anti-poliubiquitina y metodos de uso. MX336323B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32460210P 2010-04-15 2010-04-15
PCT/US2011/032468 WO2011130499A1 (en) 2010-04-15 2011-04-14 Anti-polyubiquitin antibodies and methods of use

Publications (2)

Publication Number Publication Date
MX2012011829A MX2012011829A (es) 2012-12-17
MX336323B true MX336323B (es) 2016-01-15

Family

ID=44788352

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012011829A MX336323B (es) 2010-04-15 2011-04-14 Anticuerpos de anti-poliubiquitina y metodos de uso.

Country Status (10)

Country Link
US (5) US8992919B2 (es)
EP (1) EP2558496B1 (es)
JP (2) JP6002660B2 (es)
KR (1) KR20130062264A (es)
CN (1) CN102947335B (es)
BR (1) BR112012026174A2 (es)
CA (1) CA2793503A1 (es)
MX (1) MX336323B (es)
RU (1) RU2603093C2 (es)
WO (1) WO2011130499A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007120334A2 (en) 2005-12-15 2007-10-25 Genentech, Inc. Methods and compositions for targeting polyubiquitin
JP5523345B2 (ja) 2008-01-18 2014-06-18 ジェネンテック， インコーポレイテッド Ｋ６３結合型ポリユビキチンを標的とする方法と組成物
CN102947335B (zh) 2010-04-15 2018-11-06 基因泰克公司 抗多聚遍在蛋白抗体及使用方法
US9321844B2 (en) 2011-08-05 2016-04-26 Genentech, Inc. Anti-polyubiquitin antibodies
SG11201604784XA (en) * 2013-12-13 2016-07-28 Genentech Inc Anti-cd33 antibodies and immunoconjugates
CN109152843A (zh) * 2016-05-20 2019-01-04 豪夫迈·罗氏有限公司 Protac抗体缀合物及其使用方法
EP3475298A1 (en) * 2016-06-24 2019-05-01 H. Hoffnabb-La Roche Ag Anti-polyubiquitin multispecific antibodies
KR20190120770A (ko) * 2017-02-10 2019-10-24 드래곤플라이 쎄라퓨틱스, 인크. Psma, nkg2d 및 cd16에 결합하는 단백질
EP3743081A4 (en) 2018-01-23 2021-12-01 New York University SPECIFIC ANTIBODIES OF THE DELTA 1 CHAIN OF THE T-LYMPHOCYTE RECEPTOR
RU2020131641A (ru) 2018-03-29 2022-04-29 Эйрвэй Терапьютикс, Инк. Системы и способы определения характеристик поверхностно-активных белков d (sp-d)
AU2019249273A1 (en) 2018-04-06 2020-10-15 Regeneron Pharmaceuticals, Inc. Methods of treatment using a leptin receptor agonist antibody
JP7636321B2 (ja) 2018-10-11 2025-02-26 インターシア セラピューティクス，インコーポレイティド ヒトアミリンアナログペプチド及び使用方法
WO2020154548A2 (en) * 2019-01-23 2020-07-30 New York University Antibodies specific to delta 1 chain of t cell receptor
JP2024534853A (ja) 2021-08-30 2024-09-26 ジェネンテック， インコーポレイテッド 抗ポリビキチン多重特異性抗体

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07238096A (ja) 1994-02-25 1995-09-12 S R L:Kk 抗ポリユビキチン・モノクローナル抗体およびポリユビキチンの測定方法
JP4753578B2 (ja) 2002-06-03 2011-08-24 ジェネンテック， インコーポレイテッド 合成抗体ファージライブラリー
DK1517921T3 (da) 2002-06-28 2006-10-09 Domantis Ltd Immunglobulin-enkeltvariable antigen-bindende domæner og dobbeltspecifikke konstruktioner deraf
US20050106667A1 (en) 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences
CN1845994A (zh) * 2003-08-06 2006-10-11 诺瓦提斯公司 遍在蛋白特异性蛋白酶
US20070218079A1 (en) 2004-05-12 2007-09-20 Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V. Method to induce rnai in prokaryotic organisms
DE102004049479A1 (de) 2004-10-11 2006-04-13 Scil Proteins Gmbh Proteinkonjugate zur Verwendung in Therapie, Diagnose und Chromatographie
CA2808168C (en) 2005-08-25 2018-06-12 Arizona Board Of Regents On Behalf Of The University Of Arizona Stem cell fusion model of carcinogenesis
WO2007120334A2 (en) 2005-12-15 2007-10-25 Genentech, Inc. Methods and compositions for targeting polyubiquitin
EP1808493A3 (en) 2006-01-13 2007-11-21 Hybrigenics S.A. Substrates and methods for assaying deubiquitinating enzymes activity
WO2008121813A2 (en) * 2007-03-30 2008-10-09 Genentech, Inc. Modulation of cytokine production
JP5523345B2 (ja) 2008-01-18 2014-06-18 ジェネンテック， インコーポレイテッド Ｋ６３結合型ポリユビキチンを標的とする方法と組成物
CN102947335B (zh) 2010-04-15 2018-11-06 基因泰克公司 抗多聚遍在蛋白抗体及使用方法
US9321844B2 (en) 2011-08-05 2016-04-26 Genentech, Inc. Anti-polyubiquitin antibodies

Also Published As

Publication number Publication date
US20170240620A1 (en) 2017-08-24
EP2558496A4 (en) 2014-01-01
CA2793503A1 (en) 2011-10-20
US12037385B2 (en) 2024-07-16
JP2013531468A (ja) 2013-08-08
US20150307602A1 (en) 2015-10-29
BR112012026174A2 (pt) 2019-09-24
RU2603093C2 (ru) 2016-11-20
US8992919B2 (en) 2015-03-31
RU2012148456A (ru) 2014-05-20
CN102947335A (zh) 2013-02-27
JP6316874B2 (ja) 2018-04-25
EP2558496A1 (en) 2013-02-20
CN102947335B (zh) 2018-11-06
US20210340234A1 (en) 2021-11-04
KR20130062264A (ko) 2013-06-12
US20110256133A1 (en) 2011-10-20
WO2011130499A1 (en) 2011-10-20
US11066463B2 (en) 2021-07-20
JP6002660B2 (ja) 2016-10-05
JP2016185155A (ja) 2016-10-27
MX2012011829A (es) 2012-12-17
EP2558496B1 (en) 2018-07-25
US9556262B2 (en) 2017-01-31
US10100105B2 (en) 2018-10-16
US20190100578A1 (en) 2019-04-04

Similar Documents

Publication Publication Date Title
MX2013011479A (es) Anticuerpos anti-fgfr4 y metodos de uso.
PH12013501339A1 (en) Anti-pcsk9 antibodies and methods of use
MX336001B (es) Anticuerpos anti-axl y metodos de uso.
MX2013001473A (es) Anticuerpos contra il-18r1 y usos de los mismos.
PH12014500841B1 (en) ANTI-HtrA1 ANTIBODIES AND METHODS OF USE
MX2014002053A (es) Anticuerpos anti -mcsp y metodos de uso.
MX2013015311A (es) Polipeptidos de enlace de pcsk9 y metodos de uso.
PH12014502132A1 (en) Anti-lgr5 antibodies and immunoconjugates
PH12018500046A1 (en) Anti-mesothelin antibodies and immunoconjugates
PH12014501605A1 (en) Anti-lrp5 antibodies and methods of use
MX2012011829A (es) Anticuerpos de anti-poliubiquitina y metodos de uso.
PH12014502601A1 (en) ANTI-Ly6E ANTIBODIES AND IMMUNOCONJUGATES AND METHODS OF USE
PH12017501417A1 (en) Anti-fap antibodies and methods of use
CA2924268C (en) Anti-alpha-synuclein antibodies and methods of use
MX2015012326A (es) Anticuerpos anti-crth2 y su uso.
SG10201804338PA (en) Anti-fcrh5 antibodies
UA104459C2 (uk) Антитіла проти fgfr3 і способи їх застосування
PH12015501059A1 (en) Anti-hemagglutinin antibodies and methods of use
MX2014014376A (es) Anticuerpos de anti-biotina y metodos de uso.
EP2566890A4 (en) ANTI-PAI-1 ANTIBODIES AND METHOD FOR THEIR USE
PH12013500616A1 (en) Antibody compositions and methods of use
MX381841B (es) Anticuerpos anti-jagged y métodos de uso.
MX353951B (es) Anticuerpos de anti-teofilina y metodos de uso.
MX2015010789A (es) Anticuerpos anti-pcsm.
PH12012501547A1 (en) Methods of preparing thiazolidines